{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011143","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.991132+00:00","generated_at":"2026-05-17T14:46:26.260698+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Passage Bio Q2 net loss narrows to $9.4M; cash runway into Q1 2027","bullets":["Cash, cash equivalents and marketable securities: $57.6M as of June 30, 2025 vs $91.8M a year ago; runway into Q1 2027.","Net loss of $9.4M ($2.96 per share) vs $16.0M ($5.09 per share) in Q2 2024 (adjusted for 1-for-20 reverse split).","Completed dosing of FTD-GRN Cohort 2 in upliFT-D study; all four patients treated with PBFT02.","Updated interim data: PBFT02 showed robust, durable CSF PGRN elevation and improved plasma NfL biomarker vs natural history.","Amended upliFT-D protocol submitted to trial sites and health authorities; plan to enroll Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011143","json":"https://secwatch.observer/filing/0001558370-25-011143.json","markdown":"https://secwatch.observer/filing/0001558370-25-011143.md","text":"https://secwatch.observer/filing/0001558370-25-011143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837025011143/0001558370-25-011143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837025011143/pasg-20250812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:46:26.260698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}